In a fresh shot of good news in the global battle against the coronavirus pandemic, Moderna (NASDAQ: MRNA) Wednesday reported highly encouraging preliminary results from a booster vaccine study. The phase 2 study measured the efficacy of booster shots of the company's mRNA-1273 coronavirus vaccine. The boosters were generally well tolerated, Moderna said, with most side effects being mild or moderate.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting